Business
BARDA Awards Vedanta Up to $76.9M to Advance VE303
BARDA Awards Vedanta Up to $76.9M to Advance VE303.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5166A\n PureTech Health PLC\n 30 September 2020\n \n \n \n \n 30 September 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303\n \n \n \n \n \n \n Award is first-ever by BARDA directed to advance development of a microbiome drug\n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced it has been awarded funding of $7.4 million, with the potential for up to an additional $69.5 million, from the Biomedical Advanced Research and Development Authority (BARDA) to advance clinical development of VE303 for high-risk Clostridioides difficile infection (CDI). \n \n \n \n \n \n Vedanta Biosciences is the first-ever \n recipient of a BARDA award in the microbiome field. The funding will support completion of an ongoing Phase 2 trial and further clinical development of VE303, a rationally-defined, orally-administered live biotherapeutic product (LBP) consisting of eight well-characterised commensal \n bacterial strains designed to effect robust and durable therapeutic changes in a patient's gut microbiota. \n \n A previous Phase 1a/1b study demonstrated rapid, durable, dose-dependent colonisation and accelerated restoration of gut microbiota in healthy volunteers who were pretreated with antibiotics.\n \n \n \n \n \n \n \n \n The full text of the announcement from Vedanta Biosciences is as follows:\n \n \n \n \n \n Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C.difficile Infection in High-Risk Patients\n \n \n \n \nAward is first-ever by BARDA directed to advance development of a microbiome drug\n \n \n \n \n \n CAMBRIDGE, Mass., September 30, 2020 - \n \n \n Vedanta Biosciences\n \n \n , a clinical-stage company developing a new category of therapies for immune-mediated diseases based on ration...